Aptose Biosciences Inc. (APTO)

Aptose Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Depreciation & Amortization	0.44	0.47	0.53	0.62	0.61	0.61
Share-Based Compensation	2.59	3.65	5.21	12.95	21.44	2.3
Other Operating Activities	-0.92	2.5	3.77	8.48	-0.71	1.81
Operating Cash Flow	-45.06	-44.59	-32.32	-43.3	-33.89	-21.56
Capital Expenditures	-0.03	-0.03	-0.02	-0.21	-0.08	-0.1
Change in Investments	10.97	9.99	30.09	-35	12.71	-17.27
Investing Cash Flow	10.94	9.96	30.07	-35.21	12.63	-17.37
Share Issuance / Repurchase	18.71	6.91	0.12	0.23	58.98	103.89
Other Financing Activities	-	-	-	-	-0.17	-0.44
Financing Cash Flow	18.71	6.91	0.12	0.23	58.81	103.45
Exchange Rate Effect	-0	0	-0	0.01	0.01	0.02
Net Cash Flow	-15.42	-27.72	-2.14	-78.28	37.55	64.54
Free Cash Flow	-45.09	-44.62	-32.35	-43.52	-33.97	-21.66
Free Cash Flow Per Share	-3.43	-6.61	-5.26	-7.33	-6.23	-6.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).